Assignee
SHENZHEN TARGETRX INC
CN·36 granted patents·8 pending applications·27 citations·filing 2016–2023
Top patents by PatentIndex Score
44 records- 0190US10543199B2Macrocycle and composition comprising thereofSHENZHEN TARGETRX INC·Filed 2017·Granted Jan 28, 2020·4 cites·16 claims
- 0289US11512074B2Substituted diamino heterocyclic carboxamide compound and a composition containing the compound and use thereofSHENZHEN TARGETRX INC·Filed 2019·Granted Nov 29, 2022·3 cites·13 claims
- 0388US11319317B2(Hetero)arylamide compound for inhibiting protein kinase activitySHENZHEN TARGETRX INC·Filed 2020·Granted May 3, 2022·2 cites·18 claims
- 0486US10780082B2Macrocycle and composition comprising thereofSHENZHEN TARGETRX INC·Filed 2019·Granted Sep 22, 2020·2 cites·18 claims
- 0584US10479767B2Substituted heteroaryl compound, composition containing same, and application thereofSHENZHEN TARGETRX INC·Filed 2016·Granted Nov 19, 2019·2 cites·8 claims
- 0682US11267806B2Indazole compound for use in inhibiting kinase activity, composition and application thereofSHENZHEN TARGETRX INC·Filed 2018·Granted Mar 8, 2022·2 cites·22 claims
- 0782US10995103B2Substituted boric acid compound, pharmaceutical composition comprising same, and application thereofSHENZHEN TARGETRX INC·Filed 2017·Granted May 4, 2021·2 cites·16 claims
- 0881US10875853B2(Hetero)arylamide compound for inhibiting protein kinase activitySHENZHEN TARGETRX INC·Filed 2018·Granted Dec 29, 2020·3 cites·8 claims
- 0979US10851062B2Substituted heteroaryl compound, composition containing same, and application thereofSHENZHEN TARGETRX INC·Filed 2019·Granted Dec 1, 2020·2 cites·19 claims
- 1077US11718611B2Benzenesulfonylbenazamide compound for inhibiting BCL-2 protein and composition and use thereofSHENZHEN TARGETRX INC·Filed 2018·Granted Aug 8, 2023·1 cites·8 claims
- 1176US10519193B2Steroidal compound, composition containing the same and use thereofSHENZHEN TARGETRX INC·Filed 2016·Granted Dec 31, 2019·1 cites·14 claims
- 1275US11091462B2(Hetero)arylamide compound for inhibiting protein kinase activitySHENZHEN TARGETRX INC·Filed 2018·Granted Aug 17, 2021·2 cites·17 claims
- 1374US11485729B2Substituted pyridazinone compoundSHENZHEN TARGETRX INC·Filed 2019·Granted Nov 1, 2022·1 cites·6 claims
- 1469US12264151B2Substituted diamino heterocyclic carboxamide compound and a composition containing the compound and use thereofSHENZHEN TARGETRX INC·Filed 2022·Granted Apr 1, 2025·0 cites·15 claims
- 1568US11517561B2Macrocycle and composition comprising thereofSHENZHEN TARGETRX INC·Filed 2020·Granted Dec 6, 2022·0 cites·18 claims
- 1665US2022389038A1Antiviral nucleoside reverse transcriptase inhibitorSHENZHEN TARGETRX INC·Filed 2022·Application pending·0 cites
- 1762US12076320B2Diarylpyrazole compound, composition comprising same, and use thereofSHENZHEN TARGETRX INC·Filed 2019·Granted Sep 3, 2024·0 cites·9 claims
- 1861US2025179027A1Cycloalkyl or heterocyclyl substituted heteroaryl compound, and composition and use thereofSHENZHEN TARGETRX INC·Filed 2023·Application pending·0 cites
- 1959US11459334B2Substituted pyrrolo[2,1-f][1,2,4]triazines as KIT and/or PDGFR-α inhibitorsSHENZHEN TARGETRX INC·Filed 2019·Granted Oct 4, 2022·0 cites·13 claims
- 2058US12077528B2Preparation method for deuterated macrocyclic compoundSHENZHEN TARGETRX INC·Filed 2019·Granted Sep 3, 2024·0 cites·8 claims
- 2157US11453672B2Substituted pyrazolo[1,5-a]pyrimidines as tropomyosin receptor kinase inhibitorsSHENZHEN TARGETRX INC·Filed 2018·Granted Sep 27, 2022·0 cites·10 claims
- 2256US2022380375A1Substituted aromatic fused ring derivative and composition comprising same, and use thereofSHENZHEN TARGETRX INC·Filed 2022·Application pending·0 cites
- 2355US11447512B2Antiviral nucleoside reverse transcriptase inhibitorSHENZHEN TARGETRX INC·Filed 2018·Granted Sep 20, 2022·0 cites·10 claims
- 2455US2023174554A1Solid form of macrocyclic compound, preparation therefor and use thereofSHENZHEN TARGETRX INC·Filed 2021·Application pending·0 cites
- 2554US12129266B2Substituted pyrazolo[1,5-a]pyridine compound, composition containing the same and use thereofSHENZHEN TARGETRX INC·Filed 2019·Granted Oct 29, 2024·0 cites·20 claims
- 2654US12116348B2Substituted benzimidazole compound and composition comprising sameSHENZHEN TARGETRX INC·Filed 2018·Granted Oct 15, 2024·0 cites·16 claims
- 2754US2023322717A1Solid form of pyrazine substituted nicotinamide, and preparation and use thereofSHENZHEN TARGETRX INC·Filed 2021·Application pending·0 cites
- 2853US11802113B2Substituted pyrazole compounds, compositions containing same, and use thereofSHENZHEN TARGETRX INC·Filed 2020·Granted Oct 31, 2023·0 cites·10 claims
- 2953US2022041607A1Fused bicyclic compound for inhibiting activity of tyrosine kinaseSHENZHEN TARGETRX INC·Filed 2021·Application pending·0 cites
- 3051US12312329B2Aminopyrimidine compound used for inhibiting activity of protein kinaseSHENZHEN TARGETRX INC·Filed 2019·Granted May 27, 2025·0 cites·17 claims
- 3150US11345703B2Substituted pyrazolo[1,5-a]pyrimidine macrocyclic compoundSHENZHEN TARGETRX INC·Filed 2019·Granted May 31, 2022·0 cites·14 claims
- 3250US11147802B2Substituted oxadiazole chemical compound and composition containing said chemical compound and use thereofSHENZHEN TARGETRX INC·Filed 2017·Granted Oct 19, 2021·0 cites·20 claims
- 3349US12365685B2Substituted fused aromatic ring derivative, composition and use thereofSHENZHEN TARGETRX INC·Filed 2020·Granted Jul 22, 2025·0 cites·12 claims
- 3449US11267810B2Aminopyrimidine compound and composition comprising same and use thereofSHENZHEN TARGETRX INC·Filed 2018·Granted Mar 8, 2022·0 cites·16 claims
- 3549US11111233B2Amino pyrimidine compound for inhibiting protein tyrosine kinase activitySHENZHEN TARGETRX INC·Filed 2019·Granted Sep 7, 2021·0 cites·11 claims
- 3646US11389463B2Antiviral nucleoside reverse transcriptase inhibitorSHENZHEN TARGETRX INC·Filed 2018·Granted Jul 19, 2022·0 cites·14 claims
- 3746US11358973B2Di(hetero)aryl macrocyclic compound for inhibiting protein kinase activitySHENZHEN TARGETRX INC·Filed 2019·Granted Jun 14, 2022·0 cites·12 claims
- 3845US11384069B2Diphenylaminopyrimidine compound for inhibiting kinase activitySHENZHEN TARGETRX INC·Filed 2018·Granted Jul 12, 2022·0 cites·16 claims
- 3945US11254696B2Dianilinopyrimidine compound for inhibiting kinase activitySHENZHEN TARGETRX INC·Filed 2018·Granted Feb 22, 2022·0 cites·15 claims
- 4045US2021386737A1Dihydroimidazopyrazinone compound, composition including same, and use thereofSHENZHEN TARGETRX INC·Filed 2019·Application pending·0 cites
- 4144US11746110B2Alkynyl (hetero) aromatic ring compounds used for inhibiting protein kinase activitySHENZHEN TARGETRX INC·Filed 2019·Granted Sep 5, 2023·0 cites·12 claims
- 4244US2021009613A1Arylphosphine oxides for inhibiting kinase activitySHENZHEN TARGETRX INC·Filed 2018·Application pending·0 cites
- 4343US11840535B2Alkynyl(hetero)aromatic compound for inhibiting protein kinase activitySHENZHEN TARGETRX INC·Filed 2019·Granted Dec 12, 2023·0 cites·18 claims
- 4438US11186578B2Substituted pyrrolo[3,2-d]pyrimidines and pyrazolo[4,3-d]pyrimidines as tyrosine kinase inhibitorsSHENZHEN TARGETRX INC·Filed 2017·Granted Nov 30, 2021·0 cites·12 claims
Join the waitlist — get patent alerts
Get an alert when SHENZHEN TARGETRX INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →